Aridis Pharmaceuticals (ARDS) Hits New 52-Week Low at $7.59
Aridis Pharmaceuticals Inc (NASDAQ:ARDS)’s share price reached a new 52-week low on Thursday . The stock traded as low as $7.59 and last traded at $8.54, with a volume of 10634 shares trading hands. The stock had previously closed at $8.50.
ARDS has been the subject of several research analyst reports. Zacks Investment Research raised shares of Aridis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Tuesday, November 13th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $25.00 target price on shares of Aridis Pharmaceuticals in a research note on Tuesday, November 13th. Maxim Group set a $25.00 target price on shares of Aridis Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, November 13th. Laidlaw initiated coverage on shares of Aridis Pharmaceuticals in a research note on Monday, September 10th. They set a “buy” rating and a $23.00 target price for the company. Finally, Northcoast Research initiated coverage on shares of Aridis Pharmaceuticals in a research note on Monday, September 10th. They set an “outperform” rating and a $40.00 target price for the company. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Aridis Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $25.40.
Aridis Pharmaceuticals (NASDAQ:ARDS) last posted its earnings results on Tuesday, November 13th. The company reported ($1.97) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by ($0.92). The company had revenue of $1.02 million for the quarter, compared to the consensus estimate of $0.33 million. On average, equities research analysts expect that Aridis Pharmaceuticals Inc will post -3.05 earnings per share for the current year.
Aridis Pharmaceuticals, Inc engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L.
See Also: Retained Earnings
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.